Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug
Capricor Therapeutics shares have plunged after FDA staff raised concerns regarding the efficacy and data of its Duchenne heart disease therapy.
The reporting (15)
- Roth Capital Downgrades Capricor Therapeutics to Neutral From Buy, Adjusts PT to $7 From $38 Moomoo · 47d ago
- FDA staff report throws cold water on Capricor's DMD cell therapy bid FirstWord Pharma · 47d ago
- Rosen Law Firm Encourages Capricor Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation Business Wire · 47d ago
- Adcom ‘cage match’ in store for Capricor? BioWorld News · 47d ago
- Capricor Provides Update on Deramiocel for DMD Ahead of FDA Meeting Intellectia AI · 47d ago
- FDA scientists question Capricor data; Legend CEO steps down BioPharma Dive · 47d ago
- Capricor Therapeutics Provides Update Ahead of FDA Advisory Committee Meeting on Deramiocel BLA for Duchenne Muscular Dystrophy Quiver Quantitative · 47d ago
- How FDA‑Linked HQ and Manufacturing Expansion At Capricor Therapeutics (CAPR) Has Changed Its Investment Story Yahoo Finance · 47d ago
- Capricor updates ahead of FDA advisory meeting on Duchenne muscular dystrophy therapy Deramiocel. Pluang · 47d ago
- Capricor Therapeutics (CAPR) Secures New Headquarters Tied To FDA Decision On Deramiocel simplywall.st · 47d ago
- FDA staff flags concerns for Capricor’s Duchenne heart disease therapy WTVB · 47d ago
- Stock Traders Purchase Large Volume of Call Options on Capricor Therapeutics (NASDAQ:CAPR) MarketBeat · 47d ago
- FDA staff flags data concerns about Capricor's therapy; shares plunge Reuters · 47d ago
- Is Capricor Therapeutics (CAPR) Trading At A Discount After Its Lease Deal And FDA Wait? Yahoo Finance · 47d ago
- Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug STAT · 47d ago broke it first
What happened
- Velocity & Diffusion: Coverage escalated across 14 distinct news outlets with 15 published articles, achieving a live velocity of 14.
- Primary Driver: Capricor Therapeutics shares have plunged after FDA staff raised concerns regarding the efficacy and data of its Duchenne heart disease therapy.
- Predictive Outlook: Newsylist algorithmic models forecast this story will fade from trending status over the next 24 hours.
- Source Integrity: Verified strictly against primary headline reporting under zero-hallucination protocols.
The FDA is questioning the efficacy and data associated with Capricor's therapy for Duchenne heart disease. These concerns were flagged by FDA staff ahead of a scheduled hearing.
Coverage from Reuters, STAT, and WTVB emphasizes the FDA's flags on the drug's efficacy. Following these reports, Reuters notes that company shares have plunged, while Yahoo Finance discusses whether the stock is now trading at a discount.
Attention remains on the upcoming hearing. Additionally, MarketBeat reports that stock traders have purchased a large volume of call options on Capricor Therapeutics (NASDAQ:CAPR).
Synthesized by Newsylist from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 47d ago.
Questions people are asking
What is the FDA's primary concern regarding Capricor?
FDA staff have flagged concerns regarding the efficacy and data of the company's Duchenne heart disease therapy.
How has the market reacted to the FDA news?
Shares of Capricor Therapeutics have plunged, though MarketBeat reports a large volume of call options have been purchased by traders.
When did these concerns emerge?
The concerns were raised ahead of a scheduled hearing.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
People, places & organizations
Topics
From around our network
Related trends
FDA Approves Alzheimer’s Blood Test Developed by Roche and Eli Lilly
The FDA has granted clearance to a new Alzheimer’s disease blood test developed by Roche and Eli Lilly.
US law to investigate foodborne illness outbreaks has been delayed for 15 years
A 15‑year freeze on a key food‑safety law is sparking congressional pressure as groups warn it hinders outbreak investigations.
Marketside soup sold at Walmart recalled over Listeria concerns: FDA
Marketside tomato bisque soup kits face a 29‑state recall over potential Listeria, hitting Walmart shoppers nationwide
Taylor Farms Voluntarily Recalls Fresh Jalapeños Over Salmonella Concerns
Taylor Farms recalls ready-to-eat foods and jalapeño products over salmonella concerns.
FDA approves 1st mRNA flu shot, from Moderna
The first mRNA-based influenza vaccine has received federal approval in the United States.
Nearly 12 million bottles of Rohto eye drops over sterility concerns, FDA announces
4 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.